STOCK TITAN

Precision Optics Q1 revenue rises 22% to $8.2M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Precision Optics Corporation, Inc. (POCI) reported first-quarter fiscal 2027 revenue of $8.2 million, up 22% from $6.7 million a year earlier. Production revenue was $7.4 million, up 23%, and engineering design services revenue increased 11% to $728,000. Gross margin was 22.5%, versus 14.2%. Net loss narrowed to $474,854, or $0.04 per share, from $1,637,030, or $0.21 per share. Non-GAAP Adjusted EBITDA was a loss of $223,761, versus $1,228,435. Operating cash flow was negative $672,145, compared with $78,227 provided in the prior-year quarter. Cash and cash equivalents were $8,966,889 at September 30, 2026.

The satellite optical communications program generated $2.3 million in revenue; after quarter-end, the same aerospace customer placed a $2 million follow-on production order earlier than anticipated. Precision Optics also received a follow-on engineering order from a U.S. space technology company developing a satellite constellation. The cystoscope program generated approximately $1.8 million in production revenue, and the ophthalmic program generated $581,000 as shipments increased under a $3.5 million follow-on order. A large defense company placed a $1.3 million follow-on production order, with production commencing in October 2026. Fiscal 2027 expectations remain revenue of $30 million to $33 million and Adjusted EBITDA of $(1.2) million to $(1.7) million.

3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Moderate pointRevenue increased 22% to $8.2 million in the first quarter of fiscal 2027.
  • Moderate pointGross margin was 22.5%, compared with 14.2% a year earlier.
  • Moderate pointNet loss narrowed to $474,854 from $1,637,030 year over year.

Negative

  • Moderate pointOperating cash flow was negative $672,145, versus $78,227 provided in the prior-year quarter.

Filing Explained

The quarter’s 21,638 service-related share issuance increased outstanding common shares to 10,994,430, reducing existing holders’ percentage ownership.

This Form 8-K furnishes POCI’s first-quarter fiscal 2027 earnings release under Item 2.02; the release is not deemed filed for Section 18 purposes or incorporated by reference into Securities Act filings.

The quarter’s equity statement records 21,638 common shares issued for consulting services and employees; shares outstanding were 10,994,430 at September 30, 2026, versus 10,972,792 at June 30, 2026. Issuing shares increases the total share count and reduces existing holders’ percentage ownership absent offsetting changes, so this issuance diluted their percentage interests.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Revenue $8,152,083 Three months ended September 30, 2026; $6,680,823 in the prior-year quarter
Gross margin 22.5% Compared with 14.2% in the prior-year fiscal first quarter
Net loss $(474,854) Three months ended September 30, 2026; $(1,637,030) in the prior-year quarter
Adjusted EBITDA $(223,761) Non-GAAP measure for the three months ended September 30, 2026; $(1,228,435) in the prior-year quarter
Net cash used in operating activities $(672,145) Three months ended September 30, 2026; $78,227 provided in the prior-year quarter
Cash and cash equivalents $8,966,889 At September 30, 2026
Fiscal 2027 revenue outlook $30 million to $33 million Company’s maintained fiscal-year expectation
Fiscal 2027 Adjusted EBITDA outlook $(1.2) million to $(1.7) million Company’s maintained fiscal-year expectation; non-GAAP measure
Adjusted EBITDA financial
"Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization)"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
gross margin financial
"Gross margin was 22.5%"
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
contract liabilities financial
"Changes in operating assets and liabilities"
Contract liabilities are amounts a company has been paid in advance for goods or services it still owes to customers — think of them like gift cards or prepaid subscriptions the company must fulfill later. For investors, they show promised future work or deliveries that will turn into revenue over time, reveal cash already collected, and help assess whether a firm has a backlog of obligations that could affect future earnings and cash flow.
right-of-use asset financial
"Operating lease right-of-use asset"
A right-of-use asset is the value a company records on its balance sheet for the practical use of something it leases — like the benefit of living in a rented office or using leased equipment for a set period. Investors care because it turns many leases into on-balance-sheet assets and matching liabilities, which can change reported leverage, asset base and performance metrics much like taking on a loan would.
micro-optics technical
"proprietary micro-optics"
Tiny optical components and systems whose critical features are measured in micrometres—such as miniature lenses, prisms, gratings and mirrors—designed to shape, split or focus light inside small devices. Think of them as the tiny camera or eyeglass parts built at chip scale; they matter to investors because they enable miniaturized sensors and displays, affect manufacturing cost and scalability, and influence performance in markets like smartphones, medical devices, automotive sensors and augmented-reality hardware.
single-use cystoscope medical
"single-use cystoscope program"
Revenue $8.2 million Up 22% from $6.7 million in the prior-year fiscal first quarter
Production revenue $7.4 million Up 23% from $6.0 million in the prior-year quarter
Gross margin 22.5% Compared with 14.2% in the prior-year quarter
Net loss $(474,854) Compared with $(1,637,030) in the prior-year quarter
Adjusted EBITDA $(223,761) Compared with $(1,228,435) in the prior-year quarter
Cash and cash equivalents $8,966,889 At September 30, 2026
Guidance

Fiscal 2027 revenue of $30 million to $33 million and Adjusted EBITDA of $(1.2) million to $(1.7) million.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were POCI’s Q1 FY2027 financial results?

POCI reported revenue of $8.2 million, up 22% year over year, and a net loss of $474,854, or $0.04 per share. Gross margin was 22.5%, compared with 14.2% in the prior-year quarter; non-GAAP Adjusted EBITDA was a loss of $223,761.

What is POCI’s fiscal 2027 outlook?

Precision Optics maintains its expectation for fiscal 2027 revenue of $30 million to $33 million and Adjusted EBITDA of $(1.2) million to $(1.7) million.

What follow-on production orders did POCI report?

After quarter-end, the aerospace customer associated with the satellite optical communications program placed a $2 million follow-on production order, earlier than anticipated. A large defense company also placed a $1.3 million follow-on production order, with production commencing in October 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0000867840 0000867840 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 16, 2026

 

PRECISION OPTICS CORPORATION, INC.

(Exact name of registrant as specified in its charter)

 

Massachusetts   001-10647   04-2795294
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)
         

 

550 King Street, Bldg. A, Ste. 100
Littleton
, Massachusetts
  01460-6245
(Address of principal executive offices)   (Zip Code)

 

(Registrant’s telephone number, including area code) (978) 630-1800

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐         Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐         Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐         Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐         Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common stock, par value $0.01 per share   POCI   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   
 

 

Item 2.02.Results of Operations and Financial Condition.

 

On November 16, 2026, Precision Optics Corporation, Inc. (the “Company”) issued a press release reporting its financial and operating results for the first quarter of fiscal year 2027 with financial guidance for fiscal year 2027 (the “Earnings Release”). A copy of the Earnings Release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

None of the information furnished in this Item 2.02 will be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor will it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”).

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Earnings Release issued by Precision Optics Corporation, Inc., dated November 16, 2026.
104   Cover Page Interactive Data File (embedded with the Inline XBRL document)

 

 

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PRECISION OPTICS CORPORATION, INC.
   
   
Dated: November 16, 2026 By:  /s/ Joseph N. Forkey
 

Name: Joseph N. Forkey

Title: President

 

 

 

 

 

 

 

 

 

 

 3 

 

Exhibit 99.1

 

PRECISION OPTICS CORPORATION
550 King Street, Bldg. A, Suite 100
Littleton, MA 01460
978 / 630-1800

 

NEWS RELEASE POC26-XXXX
FOR IMMEDIATE RELEASE Monday, November 16, 2026

 

Precision Optics Reports First Quarter Fiscal 2027 Financial Results

Conference Call Scheduled for Today, November 16, at 5:00 p.m. ET

 

LITTLETON, MA, November 16, 2026. Precision Optics Corporation, Inc. (Nasdaq: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced financial results for its first quarter of fiscal 2027 ended September 30, 2026.

 

Q1 2027 Financial Highlights (3 Months Ended September 30, 2026)

 

•Revenue increased 22% to $8.2 million from $6.7 million in the prior-year fiscal first quarter.
•Production revenue grew 23% to $7.4 million from $6.0 million in the prior fiscal year quarter.
•Engineering design services revenue increased 11% year over year to $728,000.
•Gross margin increased to 22.5% from 14.2% in the prior-fiscal year first quarter.
•Net loss narrowed to $475,000, or $0.04 per share, from $1.6 million, or $0.21 per share, in the first quarter of the prior fiscal year.
•Adjusted EBITDA was approximately $(0.2) million, compared with $(1.2) million in the first quarter of the prior fiscal year.
•Cash and cash equivalents were $9.0 million at September 30, 2026 compared with $9.8 million at June 30, 2026.

 

Recent Operating Highlights

 

•Generated $2.3 million in revenue during the first quarter of fiscal 2027 from the Company’s established satellite optical communications program. After quarter-end, the Company received a follow-on production order from the same top-tier aerospace customer, which was earlier than anticipated.
•Received a follow-on engineering order from a U.S. space technology company developing a new satellite constellation.
•Generated approximately $1.8 million in production revenue during the first quarter of fiscal 2027 from the single-use cystoscope program.
•Achieved revenue of $581,000 during the first quarter of fiscal 2027 from the single-use ophthalmic program as shipments increased under the $3.5 million follow-on order.
•Received a $1.3 million follow-on production order from a large defense company with production that commenced in October 2026.

 

Fiscal 2027 Financial Outlook

 

The Company maintains its expectation for fiscal year 2027 revenue to be in the range of $30 million to $33 million and for Adjusted EBITDA to be in a range of $(1.2) million to $(1.7) million.

 

 

 

 1 

 

 

“Revenue grew 22% year over year to $8.2 million, led by a 23% increase in production revenue. Higher volumes and more efficient manufacturing helped lift gross margin and improved our Adjusted EBITDA,” said Dr. Joe Forkey, CEO of Precision Optics. “Our established satellite optical communications program generated $2.3 million in first-quarter revenue, and the same customer placed a $2 million follow-on production order after quarter-end, earlier than we anticipated. Satellite communications are becoming an increasingly key market for us following the receipt of a follow-on engineering order from a second U.S. space technology customer to support the design of its new satellite constellation.”

 

“We continued to make operational progress with our single-use medical device programs. The cystoscope program generated $1.8 million in production revenue, and our ophthalmic program delivered revenue of $581,000, as shipments increased under its $3.5 million follow-on order.”

 

The following table summarizes the unaudited results for the three months ended September 30, 2026 and 2025

 

   Three Months 
   Ended September 30 
   2026   2025 
Revenues  $8,152,083   $6,680,823 
           
Gross Profit   1,837,851    946,358 
           
Stock Compensation Expenses   229,278    301,639 
Other   2,126,882    2,239,974 
Total Operating Expenses   2,356,161    2,541,613 
           
Operating Income (Loss)   (518,310)   (1,595,255)
           
Net Income (Loss)   (474,854)   (1,637,030)
           
Income (Loss) per Share          
Basic & Fully Diluted  $(0.04)  $(0.21)
           
           
Weighted Average Common Shares Outstanding          
Basic & Fully Diluted   10,974,771    7,714,701 

 

Conference Call Details

 

Monday, November 16, 2026, at 5:00 p.m. ET. Participants may dial 1-844-735-3662 (U.S. and Canada) or 1-412-317-5705 (international).

 

Live webcast and webcast replay: https://app.webinar.net/7KDE27PWeyo.

 

A telephone replay will be available through November 23 at 1-855-669-9658 (U.S. and Canada) or 1-412-317-0088 (international). The replay access code is 7453200.

 

 

 

 2 

 

 

About Precision Optics Corporation

 

Founded in 1982, Precision Optics is a vertically integrated optics company focused on leveraging its proprietary micro-optics, multi-channel and ultra-high precision imaging and digital imaging technologies across the medical device, defense/aerospace and satellite communications markets. Through its Systems Manufacturing, Engineering, Ross Optical and Micro-Optics Lab operations, the Company provides services from new product concept and design through volume production. Its in-house optical, mechanical, electrical and systems engineering, prototyping, regulatory support, fabrication, assembly and manufacturing capabilities enable it to develop next-generation solutions for demanding customer requirements. In medical devices, Precision Optics supports minimally invasive and robotic surgery with micro-endoscopes, single-use and reusable endoscopes, digital imaging and related optical assemblies. In defense/aerospace and satellite communications, the Company applies its micro-optics and opto-mechanical expertise to applications requiring high quality and optimized size, weight and power. Ross Optical complements these capabilities through global sourcing, inspection and production of custom and catalog optics. For more information, please visit www.poci.com.

 

Non-GAAP Financial Measures

 

Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“non-GAAP”). The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). In addition to these items, Adjusted EBITDA excludes from Net Income (Loss) the effect of stock-based compensation.

 

This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.

 

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.

 

Precision Optics is unable to provide a reconciliation of forward-looking Adjusted EBITDA guidance to net income (loss), the most directly comparable GAAP financial measure, without unreasonable efforts because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including stock-based compensation expense, which may vary significantly based on stock price and other factors outside the Company’s control. The unavailable information could have a significant effect on the Company’s GAAP financial results.

 

 

 

 3 

 

 

About Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of U.S. federal securities laws, including statements concerning our fiscal year 2027 revenue and Adjusted EBITDA guidance, as well as the timing and expectations for certain production orders. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the Company), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company’s products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company’s filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

 

Investor Contact:

Robert Blum

Lytham Partners, LLC

602-889-9700

poci@lythampartners.com

 

 

 

 

 

 

 

 4 

 

 

PRECISION OPTICS CORPORATION, INC.

BALANCE SHEETS

(UNAUDITED)

 

   September 30,   June 30, 
   2026   2026 
ASSETS          
Current Assets:          
Cash and cash equivalents  $8,966,889   $9,841,142 
Accounts receivable, net of allowance for credit losses of $109,055 at September 30, 2026 and $108,220 at June 30, 2026   5,371,290    5,944,412 
Inventories, net   3,518,893    3,829,414 
Prepaid expenses   586,022    494,488 
Total current assets   18,443,094    20,109,456 
           
Fixed Assets:          
Machinery and equipment   3,427,461    3,410,813 
Leasehold improvements   1,226,171    1,226,171 
Furniture and fixtures   674,445    645,046 
    5,328,077    5,282,030 
Less—accumulated depreciation and amortization   4,415,080    4,394,317 
Net fixed assets   912,997    887,713 
           
Operating lease right-of-use asset   2,229,155    2,300,866 
Patents, net   206,597    212,889 
Goodwill   8,824,210    8,824,210 
Total other assets   11,259,962    11,337,965 
TOTAL ASSETS  $30,616,053   $32,335,134 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current Liabilities:          
Current maturities of long-term debt  $577,898   $577,898 
Accounts payable   2,620,358    3,582,674 
Customer advances   2,342,890    2,498,501 
Accrued compensation and other   1,619,014    1,843,368 
Current portion of operating lease liability   335,011    325,500 
Total current liabilities   7,495,171    8,827,941 
           
Long-term debt, net of current maturities   562,023    711,305 
Operating lease liability, net of current portion   2,358,873    2,446,576 
Total liabilities   10,416,067    11,985,822 
           
Stockholders’ Equity:          
Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding – 10,994,430 shares at September 30, 2026 and 10,972,792 at June 30, 2026   109,944    109,728 
Additional paid-in capital   81,165,417    80,840,105 
Accumulated deficit   (61,075,375)   (60,600,521)
Total stockholders’ equity   20,199,986    20,349,312 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $30,616,053   $32,335,134 

 

 

 

 5 

 

 

PRECISION OPTICS CORPORATION, INC.

STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED

SEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

   Three Months
Ended September 30,
 
   2026   2025 
Revenues  $8,152,083   $6,680,823 
           
Cost of Goods Sold   6,314,232    5,734,465 
Gross Profit   1,837,851    946,358 
           
Research and Development Expenses   306,215    311,840 
Selling, General and Administrative Expenses   2,049,946    2,229,773 
Total Operating Expenses   2,356,161    2,541,613 
           
Operating Loss   (518,310)   (1,595,255)
           
Other income (expense):          
Interest expense   (30,121)   (41,775)
Interest income   73,577    – 
           
Net Loss  $(474,854)  $(1,637,030)
           
Loss Per Share:          
Basic & Fully Diluted  $(0.04)  $(0.21)
           
Weighted Average Common Shares Outstanding:          
Basic & Fully Diluted   10,974,771    7,714,701 

 

 

 

 

 

 

 

 6 

 

 

PRECISION OPTICS CORPORATION, INC.

STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE THREE MONTHS ENDED

sEPTEMBER 30, 2026 AND 2025

(UNAUDITED)

 

   Three Month Period Ended September 30, 2026 
   Number of
Shares
   Common
Stock
   Additional
Paid-in
Capital
   Accumulated
Deficit
   Total
Stockholders’
Equity
 
                     
Balance, July 1, 2026   10,972,792   $109,728   $80,840,105   $(60,600,521)  $20,349,312 
Issuance of common stock for consulting services and employees   21,638    216    96,034    –    96,250 
Stock-based compensation   –    –    229,278    –    229,278 
Net loss   –    –    –    (474,854)   (474,854)
Balance, September 30, 2026   10,994,430   $109,944   $81,165,417   $(61,075,375)  $20,199,986 

 

   Three Month Period Ended September 30, 2025 
   Number of
Shares
   Common
Stock
   Additional
Paid-in
Capital
   Accumulated
Deficit
   Total
Stockholders’
Equity
 
                     
Balance, July 1, 2025   7,714,701   $77,147   $69,152,317   $(56,970,630)  $12,258,834 
Stock-based compensation   –    –    301,639    –    301,639 
Net loss   –    –    –    (1,637,030)   (1,637,030)
Balance, September 30, 2025   7,714,701   $77,147   $69,453,956   $(58,607,660)  $10,923,443 

 

 

 

 

 

 

 

 7 

 

 

PRECISION OPTICS CORPORATION, INC.

STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED

September 30, 2026 AND 2025

(UNAUDITED)

 

   Three Months
Ended September 30,
 
   2026   2025 
Cash Flows from Operating Activities:          
Net Loss  $(474,854)  $(1,637,030)
Adjustments to reconcile net loss to net cash used in operating activities -          
Depreciation and amortization   65,271    65,181 
Stock-based compensation expense   235,528    301,639 
Non-cash interest expense   4,801    4,608 
Non-cash operating lease expense   (6,481)   49,322 
(Gain) Loss on disposal of fixed assets   (36,238)   34,506 
Changes in operating assets and liabilities -          
Accounts receivable, net   573,122    148,797 
Inventories, net   310,521    (318,196)
Prepaid expenses   (91,534)   (14,240)
Accounts payable   (962,316)   1,099,235 
Contract liabilities   (155,611)   208,843 
Accrued compensation and other   (134,354)   135,562 
Net cash provided by (used in) operating activities   (672,145)   78,227 
           
Cash Flows from Investing Activities:          
Purchases of fixed assets   (84,263)   (304,731)
Proceeds from sale of fixed assets   36,238    3,000 
Additional patent costs   –    (58)
Net cash used in investing activities   (48,025)   (301,789)
           
Cash Flows from Financing Activities:          
Payments of capital lease obligations   –    (8,985)
Payments of debt issuance costs   (5,000)   – 
Payments of long-term debt   (149,083)   (149,083)
Net cash used in financing activities   (154,083)   (158,068)
           
Net decrease in cash and cash equivalents   (874,253)   (381,630)
Cash and cash equivalents, beginning of period   9,841,142    1,773,735 
           
Cash and cash equivalents, end of period  $8,966,889   $1,392,105 
           
Supplemental disclosure of cash flow information:          
Cash paid during the period for income taxes  $–   $2,600 
Cash paid during the period for interest  $25,320   $37,167 
Issuance of common stock for employee services  $96,250   $– 
Operating right-of-use assets obtained in exchange for operating lease liabilities  $–   $2,632,584 
Lease improvements financed by landlord  $–   $218,750 

 

 

 

 8 

 

 

PRECISION OPTICS CORPORATION, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

ADJUSTED EBITDA

 

 

   Three Months Ended 
   Ended September 30, 
   2026   2025 
Net Income (loss) (GAAP)  $(474,854)  $(1,637,030)
           
Stock based compensation   229,278    301,639 
           
Depreciation and amortization   65,271    65,181 
           
Interest Expense   30,121    41,775 
           
Interest Income   (73,577)   – 
           
Adjusted EBITDA (non-GAAP)  $(223,761)  $(1,228,435)

 

 

 

 

 

 

 

 

 

 

 

 

 9 

 

Filing Exhibits & Attachments

4 documents

Keep reading